Fibroscan as A Noninvasive Tool in the Assessment of Fibrosis in Non Alcoholic Fatty Liver Disease (NAFLD) And It's Correlation with Fibrosis 4 Score (FIB4) and NAFLD Fibrosis Score (NFS).

Background: Non alcoholic fatty liver disease(NAFLD) is emerging as an important cause of liver disease in India. The prevalence of NAFLD in Indian population is reported to be between 9-32% which is almost comparable to the Western countries. NAFLD is considered the hepatic manifestation of the metabolic syndrome and shares a strong association with Type 2 diabetes mellitus. Materials and methods - It is a Prospective Observational study, conducted between October 2018 to April 2020 on 200 NAFLD patients detected with fatty liver on abdominal ultrasound examination. Results- In our study, the mean age of NAFLD patients is 47. 9 years. The prevalence of NAFLD increases with increasing age. The prevalence of NAFLD in men is higher with 117(58. 5%) males and 87(41. 5%) female. The prevalence of components of metabolic syndrome, i. e Obesity/overweight, hypertension, dyslipidemia and T2DM is 39. 5%, 18. 5%, 69% and 46% respectively. Based on Fibroscan examination the mean stiff ness score is 7. 09 (SD 5. 07) kpa. Conclusion- The combined use of Fibroscan with other non invasive biomarkers is useful in detecting the advanced fibrosis in NAFLD patients and also for the follow up of patients with minimal disease, thus avoiding the need for liver biopsy. [ABSTRACT FROM AUTHOR]